1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-28.61%
Cash & equivalents declining -28.61% while Drug Manufacturers - Specialty & Generic shows -2.55% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
-16.01%
Short-term investments yoy growth below half the Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would question if the firm lacks surplus cash or is facing liquidity stress.
-26.37%
Cash + STI yoy growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -6.03%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
37.94%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.34%. Jim Chanos might see a serious red flag in ballooning receivables.
115.87%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.51%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
16.68%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
7.37%
Current assets growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.75%. Joel Greenblatt sees a potential liquidity edge if well allocated.
13.78%
PP&E growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.71%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
3.82%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
-7.82%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -0.08%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-0.75%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
-20.61%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
200.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
-42.63%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-2.59%
Below half the Drug Manufacturers - Specialty & Generic median of 0.21%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
-1.21%
Below half the Drug Manufacturers - Specialty & Generic median of 0.69%. Jim Chanos might see potential stagnation or distress vs. peers.
153.94%
Payables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 3.58%. Jim Chanos might see a warning sign of stressed supplier payments.
282.05%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-79.29%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-19.62%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
-41.37%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
64.74%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 2.01%. Jim Chanos suspects potential working capital strain.
22.93%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
-20.80%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
-55.93%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-15.19%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -1.12%. Jim Chanos suspects a red flag in ballooning future obligations.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects hidden or rapidly growing miscellaneous liabilities.
13.49%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.20%. Jim Chanos suspects an alarming rise in overall leverage.
1.19%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-104.72%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -0.93%. Joel Greenblatt sees stronger retained profit growth vs. peers.
No Data
No Data available this quarter, please select a different quarter.
45.18%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
-4.36%
Below half Drug Manufacturers - Specialty & Generic median of 0.52%. Jim Chanos suspects slower net worth growth or losses vs. peers.
-1.21%
Below half Drug Manufacturers - Specialty & Generic median of 0.69%. Jim Chanos suspects a major slowdown or distress.
-19.87%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
41.69%
Below half Drug Manufacturers - Specialty & Generic median of -0.06%. Joel Greenblatt sees a stronger deleveraging trend than peers.
68.61%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.83%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
